WXXWY WUXI BIOLGCS ADR
- 4.230
- -0.300-6.62%
WUXI BIOLGCS ADR News
Trump Government Likely to Still Pass Biosecure Act -- Market Talk
Hong Kong stocks are active | CRO concepts generally rise, medical insurance negotiations support innovative drugs, and under the environment of interest rate cuts, global biomedical financing will rebound.
The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories (06821) rose by 4.95%, to HKD 59.4; Tigermed (03347) rose by 4.94%, to HKD 38.25; Wuxi Apptec (02359) rose by 3.88%, to HKD 53.5.
Wuxi bio launches the technology platform WuXia RidGS, empowering customers to develop non-antibiotic cell lines.
Shanghai, October 28, 2024 / PRNewswire / -- China's leading contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics (2269.HK) announces the launch of the WuXia RidGS cell line construction platform based on high-yield glutamine synthetase (GS) in Chinese hamster ovary (CHO) expression system. The platform serves as a non-antibiotic cell line development tool, utilizing zinc finger nuclease (ZFN) technology to knock out the endogenous GS gene in CHO cells. WuXia RidGS is derived from
HK Stocks Update: Pharmaceutical stocks continue to strengthen, AstraZeneca-B (01541) expands its gains in the afternoon. Hong Kong approval mechanism will be extended to all new drugs starting from November.
Pharmaceutical stocks continue to strengthen, as of the time of publication, Yimengangke-B (01541) rose by 22.76% to 7.65 Hong Kong dollars; zai lab (09688) rose by 15.25% to 25.7 Hong Kong dollars; Heyu-B (02256) rose by 8.82% to 4.32 Hong Kong dollars; tigermed (03347) rose by 11.65% to 41.2 Hong Kong dollars; wuxi bio (02269) rose by 6.68% to 17.56 Hong Kong dollars.
Trending Industry Today: TIGERMED Leads Gains In CRO Stocks
Wuxi Bio [02269] is now trading at 17.3 Hong Kong dollars, with a rise of 5.10%.
As of 10:50, Wuxi Bio [02269] reported a share price of 17.3 Hong Kong dollars, up 0.84 Hong Kong dollars or 5.10% from the previous closing price of 16.46 Hong Kong dollars, with a turnover of 458.7831 million Hong Kong dollars. The highest price today is 17.3 Hong Kong dollars, and the lowest price is 16.42 Hong Kong dollars. Based on the closing price from yesterday, the 10-day average price is 16.49 Hong Kong dollars, the 50-day average price is 13.77 Hong Kong dollars, and the current PE ratio is 18.29 times. The 14-day relative strength index is reported as 42.09.
Hong Kong stocks abnormal | The concept of CRO rose sharply in early trading, with intensive support policies for innovative drugs coming out, and the Fed may cut interest rates again in November.
Early concept of CRO rose in the morning session, as of the deadline, Frontage (01521) rose 8.45%, closing at 0.77 Hong Kong dollars; Tigermed (03347) rose 5.28%, closing at 38.85 Hong Kong dollars; Asymchem Laboratories (06821) rose 5.16%, closing at 57.1 Hong Kong dollars; Pharmaron (03759) rose 4.56%, closing at 15.6 Hong Kong dollars; Wuxi Bio (02269) rose 3.77%, closing at 17.08 Hong Kong dollars.
Hong Kong stock market anomaly | CRO concept stocks are all rebounding, with many stocks rising by more than 10%. The National Medical Products Administration has deployed a pilot reform of segmented production of biological products.
CRO concept stocks are all rebounding, as of the time of publication, frontage (01521) rose by 14%, to 0.57 Hong Kong dollars; pharmaron (03759) rose by 12.59%, to 14.84 Hong Kong dollars; tigermed (03347) rose by 11.11%, to 38 Hong Kong dollars; wuxi bio (02269) rose by 10.54%, to 16.78 Hong Kong dollars.
The Hang Seng Index further expanded its gains, with the Hang Seng Index rising by 3.44%. Meituan (03690) increased by 8.93%.
King Wai Financial News | The Hang Seng large cap index further expanded its gains, with Hang Seng Index up 3.44%, Hang Seng China Enterprises Index up 3.89%, and Hang Seng Tech Index rising by 5.8%. Semiconductor Manufacturing International Corporation (00981) led the gains in blue-chips with a 15.96% increase, while BYD Electronic (00285) rose by 9.32%, Wuxi Bio (02269) by 9.22%, and Ali Health (00241) by 8.63%. In the ATMX, Meituan (03690) increased by 8.93%, Xiaomi Group (01810) by 5.61%, Tencent (00700) by 4.65%, Alibaba (09988) rose.
Trending Industry Today: ZAI LAB Leads Gains In Biotechnology Stocks
Trending Industry Today: PHARMARON Leads Gains In CRO Stocks
WuXi Biologics Receives ESG Corporate Platinum Award From The Asset for Fourth Consecutive Year
WuXi Biologics Receives ESG Corporate Platinum Award From The Asset for Fourth Consecutive Year
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has
Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks
Trending Industry Today: TIGERMED Leads Losses In CRO Stocks
Trending Industry Today: WUXI XDC Leads Losses In Biotechnology Stocks
Wuxi Bio (02269.HK) spent 49.765 million Hong Kong dollars on October 8 to buy back 2.53 million shares.
Gelonghui October 8th | wuxi bio (02269.HK) announced that on October 8th, it spent 49.765 million Hong Kong dollars to repurchase 2.53 million shares.
Trending Industry Today: TIGERMED Leads Losses In Biotechnology Stocks
[Brokerage Focus] China Post Securities expects the pharmaceutical sector to continue to rise uniformly, suggesting prioritizing the layout of various segmented sectors and leading companies in the first and second tiers during the general rise phase.
Golden Herald Financial News | China Post Securities stated that since the end of September, the pharmaceutical sector has been boosted by the national comprehensive incremental policy, solidly promoting the economy towards a higher-quality structure under the heavy bullish push, leading to a rapid rebound of the index by about 29%, reversing the continuous decline of nearly 4 years. Looking at the current PE (TTM), A-share pharmaceuticals are at 32 times, and Hong Kong stocks at 23 times. The previous continuous decline has already deviated from the fundamentals. The bank believes that the increase in market risk appetite will accelerate the sector's valuation repair. As of H1 2024, the institutions hold a 7.3% stake in the CSI SWS Health Care Index sector, which, although slightly lower than the end of 2023, still remains at a historically high level, indicating a general positive sentiment among institutions.
What happened during the National Day holiday at home and abroad? Here is a summary of important financial news.
①Shanghai Stock Exchange: From October 8th, the acceptance time for designated trading order instructions will be extended; Goldman Sachs has raised the Chinese stock market to "overweight", expecting a further increase of 15-20%; ②Hong Kong stocks are booming with a high increase in the number of new brokerage accounts and margin trading data within the past week; Many places have introduced optimized policies for real estate, and the market has responded positively.
Analysis
Price Target
No Data
No Data